Literature DB >> 7351004

Treatment of gram-positive septicemia in cancer patients.

P A Pizzo, S Ladisch, K Ribichaud.   

Abstract

Seventy-eight pediatric cancer patients were treated for gram-positive bacterial septicemia during a 10-year period (1968-1977). Sixty-one (78%) of the patients were granulocytopenic (PMNs less than 500/mm3) at the onset of the septic episode. All the patients whose granulocytopenia resolved (PMNs greater than 500/mm3) within one week of therapy recovered without sequelae. However, 7 of 15 patients (47%) who remained granulocytopenic for more than 7 days and who were treated with a single antibiotic developed a second sepsis with a gram-negative organism. In contrast, second infections were not observed in 24 patients with PMNs less than 500/mm3 for more than 7 days who were treated with broad spectrum antibiotics (p less than 0.002), suggesting that a broad-spectrum antibiotic regimen may be preferable when a cancer patient has prolonged granulocytopenia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351004     DOI: 10.1002/1097-0142(19800101)45:1<206::aid-cncr2820450133>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.

Authors:  Aslıhan Demirel; Fehmi Tabak; M Cem Ar; Bilgül Mete; Şeniz Öngören; Mücahit Yemişen; Reşat Özaras; Emre Eşkazan; Zafer Başlar; Ali Mert; Teoman Soysal; Burhan Ferhanoğlu; Yıldız Aydın; Recep Öztürk
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

3.  Secondary infections in cancer patients with febrile neutropenia.

Authors:  Alpay Azap; Gülden Yılmaz Bozkurt; Meltem Kurt Yüksel; Hakan Kutlu; Pervin Topçuoğlu; Adalet Aypak; Hamdi Akan
Journal:  Turk J Haematol       Date:  2012-10-05       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.